SCHEMBL3238530

SCHEMBL3238530

O=C1NN2c3ccccc3CC2C2NCCCC12

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.38
SRD5A1 P18405 3/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR2C P28335 3/20 0.33
HTR2A P28223 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
AADAT Q8N5Z0 2/20 0.32
GOT1 P17174 1/20 0.32
KYAT1 Q16773 1/20 0.32
KYAT3 Q6YP21 1/20 0.32
HTR2B P41595 2/20 0.32
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3241251 0.80 NOTUM (0.41) NOTUMMEN1KMT2AHTR2CHTR2A
SCHEMBL3250303 0.76 MEN1 (0.37) NOTUMMEN1KMT2AKDM4EALDH1A1
SCHEMBL3242963 0.64 MEN1 (0.46) NOTUMMEN1KMT2AALDH1A1MAPT
SCHEMBL3246762 0.64 CYP3A4 (0.41) NOTUMMEN1KMT2AKDM4EALDH1A1
SCHEMBL3246780 0.64 CYP3A4 (0.41) NOTUMMEN1KMT2AKDM4EALDH1A1
SCHEMBL14557493 0.63 G6PD (0.41) MEN1KMT2AALDH1A1GAA
SCHEMBL23053187 0.62 HTR2A (0.35) NOTUMMEN1KMT2AHTR2CHTR2A
SCHEMBL3242982 0.61 MEN1 (0.43) SRD5A1MEN1KMT2AHTR2CHTR2A
SCHEMBL11825590 0.59 MEN1 (0.50) MEN1KMT2AHTR2CHTR2AKDM4E
SCHEMBL9964021 0.58 DRD2 (0.49) HTR2CHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2102204-B1 NEW AMINOPYRROLO[1,2- A]INDOLE ET AMINOPYRIDAZINO[1,6-A]INDOLE DERIVATIVES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME SERVIER LAB (FR) 2010-05-05 EP claimed
EP-2102204-B1 NEW AMINOPYRROLO[1,2- A]INDOLE ET AMINOPYRIDAZINO[1,6-A]INDOLE DERIVATIVES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME SERVIER LAB (FR) 2010-05-05 EP disclosed
US-20090298813-A1 USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES LES LABORATOIRES SERVIER (FR) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298813-A1 USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES NLN, GAP43, SNCA NOTUM 2208/4885SRD5A1 4440/4885MEN1 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.